Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1( L ) ASCORBATO DI CALCIO1件: Calcium---2件: 96, 97
2(+) erythromefloquine----1件: 46
3(+) isomer of racemic mefloquine1件: Mefloquine1件: D04895 --1件: 46
4(+) isomer or racemic mefloquine1件: Mefloquine1件: D04895 --1件: 46
5(+)- Epicatechin1件: Epicatechin---1件: 113
6(+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid2件: Naproxen,
Propanoic acid		2件: D00118 ,
D02310 		2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 271
7(+)-Epicatechin1件: Epicatechin---1件: 113
8(+)erythromefloquine----1件: 46
9(-)-3-(4-Aminophenyl)-2-methoxypropionic acid----1件: 97
10(-)-Epicatechin1件: Epicatechin---2件: 86, 113
11(-)-trans-delta-9-Tetrahydrocannabinol1件: Dronabinol1件: D00306 2件: CNR1,
CNR2 💬		4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬1件: 13
12(1-3)-beta-D-Glucan (BDG) assay (Fungitell)----1件: 107
13(1-3)-ß-D-Glucan (BDG) assay (Fungitell)----1件: 107
14(11C)PE2I----1件: 6
15(18)F-FDG----1件: 85
16(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide----1件: 11
17(2)-epigallocatechin-3-gallate (EGCG)2件: Epigallocatechin,
Epigallocatechin gallate		---1件: 8
18(2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)----1件: 6
19(2R)-2-Propyloctanoic acid1件: Arundic acid1件: D06296 --1件: 2
20(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide----1件: 309
21(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide----1件: 309
22(3beta, 5beta, 25R)-spirostan-3-ol----1件: 6
23(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-----1件: 46
24(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,----1件: 46
25(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-----1件: 46
26(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,----1件: 46
27(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1-----1件: 46
28(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1-----1件: 46
29(3ß, 5ß, 25R)-spirostan-3-ol----1件: 6
30(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile----1件: 231
31(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’-----1件: 79
32(6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate----1件: 2
33(6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol----1件: 6
34(7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine----1件: 301
35(CDP6038----1件: 46
36(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime----1件: 161
37(IM) AVONEX®1件: Interferon beta-1a1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
38(minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate----1件: 6
39(Pyr1)apelin-13----1件: 86
40(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide----1件: 13
41(R)-(-)-2-Propyloctaroic acid----1件: 2
42(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-1件: Pyrazole---1件: 75
43(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE1件: Pyrazole---1件: 75
44(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE1件: Pyrazole---1件: 75
45(R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid2件: Butyric Acid,
Chloride ion		1件: D05866 --1件: 97
46(R)-[N-metil-11C1-PK11195(PK)----1件: 127
47(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE1件: Pyrazole---1件: 58
48(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE1件: Pyrazole---1件: 58
49(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE----1件: 58
50(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate1件: Piperazine6件: D00807 ,
D01393 ,
D02127 ,
D02145 ,
D05486 ,
D06224 		--1件: 272
51(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate1件: Piperazine6件: D00807 ,
D01393 ,
D02127 ,
D02145 ,
D05486 ,
D06224 		--1件: 272
52(R)-troloxamide quinone----1件: 6
53(RS)-baclofen1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 10
54(RS)-baclofen, naltrexone hydrochloride and D-sorbitol3件: Baclofen,
Naltrexone,
Sorbitol		4件: D00096 ,
D00241 ,
D02095 ,
D05113 		5件: GABBR1,
GABBR2,
OPRD1,
OPRK1,
OPRM1 💬		9件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 10
55(S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol----1件: 6
56(S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate----1件: 6
57(S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid----1件: 97
58(S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid----1件: 86
59(S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one----1件: 240
60(S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM----1件: 86
61(S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM----1件: 86
62(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo----1件: 284
63(S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide3件: Hydroxide ion,
Magnesium,
Magnesium hydroxide		1件: D00731 --1件: 284
64(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m----1件: 284
65(S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide3件: Hydroxide ion,
Magnesium,
Magnesium hydroxide		1件: D00731 --1件: 284
66(S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride----1件: 97
67(S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben----1件: 97
68(S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride----1件: 97
69* D.3.4 Solution for infusion in pre-filled syringe----1件: 97
70* D.3.4 Solution for injection in pre-filled syringe----1件: 97
71* D.3.4 Solution for injection/infusion in pre-filled syringe----1件: 97
72* D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg----1件: 41
73* D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg----1件: 41
74**Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter.1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
75-aminosalicylic acid1件: Aminosalicylic acid1件: D00162 --2件: 96, 97
760 mg Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 44
770 mg tropicamide1件: Tropicamide1件: D00397 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
780,25 mg RPC1063----1件: 96
790,5 mg Fingolimod1件: Fingolimod1件: D10001 1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
800,5 mg Prevenar i.m.----1件: 51
810,5 mg seasonal influenza vaccine i.m.----1件: 51
820.005% Lacripep----1件: 53
830.01% Lacripep----1件: 53
840.02% Fm, SH----1件: 53
850.02% Fm, SH, 0.05% CsA----1件: 53
860.02% Fm, SH, AS----1件: 53
870.04 mg Lu AE04621----1件: 6
880.05%cyclosporin eye drop1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 38
890.08 mg Lu AE04621----1件: 6
900.12% saline----1件: 299
910.15mg KPG-818 dose----1件: 49
920.2 mg Lu AE04621----1件: 6
930.25 mg RPC103----1件: 97
940.25 mg RPC1063----3件: 13, 96, 97
950.25mg RPC103----1件: 97
960.25mg RPC1063----2件: 13, 97
970.3 mg tropicamide1件: Tropicamide1件: D00397 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
980.4 mg Lu AE04621----1件: 6
990.4mL prefilled syringes----1件: 107
1000.5 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1010.5 mg RPC1063----2件: 13, 97
1020.5% marcaine----1件: 70
1030.5mg RPC1063----1件: 13
1040.6 mg Lu AE04621----1件: 6
1050.6mg KPG-818 dose----1件: 49
1060.7mL prefilled syringes----1件: 107
1070.8 mg Lu AE04621----1件: 6
1080.9% Isotonic Saline (IS)----1件: 299
1090.9% Isotonic Saline (IS), 4mL----1件: 299
1100.9% normal saline (control)----1件: 299
1110.9% physiological saline----1件: 266
1120.9% saline----2件: 6, 70
1130.9% sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --4件: 6, 14, 51, 53
1140.9% sodium chloride (normal saline)2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 6
1150.9% Sodium Chloride Injection2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 168
1160.9% w/v isotonic sodium chloride solution2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 50
1170.9% w/v sodium chloride solution2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 299
1180000----1件: 3
11900000----2件: 6, 96
120000000----1件: 6
121000000000----1件: 66
1220002-8971----1件: 70
12300070500----1件: 60
12400201600----1件: 229
12500244301----1件: 274
12600258901----1件: 85
12700305800----2件: 53, 160
12800319301----1件: 60
12900322900----1件: 85
130009-0----1件: 6
131009-1----1件: 6
132009-2----1件: 6
133009-3----1件: 6
134009-4----1件: 6
135009-5----1件: 6
136009-A0----1件: 6
137009-A1----1件: 6
138009-A2----1件: 6
139009-A3----1件: 6
1400109-0012A 100 mg/ml----1件: 46
1410109-0012A 25 mg/ml----1件: 46
1420109-0012A 50 mg/ml----1件: 46
1430114-0006B----2件: 46, 96
144023145028----1件: 6
145032166011----1件: 13
146033283045----1件: 13
147033841----1件: 299
148034091165----1件: 13
149035418060----1件: 13
150043906039----1件: 6
151045251016----1件: 19
1520881----2件: 46, 271
1530C23----1件: 67
1541 - Andrographis paniculata p/st extract----1件: 13
1551 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
1561 mg QD to 15 mg QD PF-066497511件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
1571 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)1件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
1581 mg RPC1063----2件: 13, 97
1591 mg tropicamide1件: Tropicamide1件: D00397 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
1601 mg/kg CNTO 136----1件: 49
1611 ml 0.9 % NaCl----1件: 46
1621% lignocaine1件: Lidocaine3件: D00358 ,
D02086 ,
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 84
1631% Steroid Cream----1件: 13
1641) Inosine 5'-monophosphate1件: Inosine1件: D00054 --1件: 17
1651,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol)1件: Glycerin1件: D00028 --1件: 79
1661,5 (Butylimino)-1,5-dideoxy-D-glucitol1件: Sorbitol1件: D00096 --1件: 299
1671,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c----1件: 46
1681- Deoxygalactonojirimycin----1件: 19
1691-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride1件: Piperazine6件: D00807 ,
D01393 ,
D02127 ,
D02145 ,
D05486 ,
D06224 		--1件: 58
1701-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one----1件: 17
1711-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID2件: Butyric Acid,
Indole		1件: D05866 --1件: 51
1721-20190----1件: 93
1731-22460----1件: 51
1741-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid----1件: 299
1751-Deoxygalactonojirimycin1件: Migalastat1件: D10359 --1件: 19
1761-deoxygalactonojirimycin hydrochloride1件: Migalastat1件: D10359 --1件: 19
1771-deoxynojirimycin1件: Duvoglustat1件: D09605 1件: GAA 💬4件: Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬1件: 256
1781-deoxynojirimycin hydrochloride1件: Duvoglustat1件: D09605 1件: GAA 💬4件: Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬1件: 256
1791-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone----1件: 13
1801. Tesofensine (NS 2330)1件: Tesofensine---1件: 6
1811.0 mg Lu AE04621----1件: 6
1821.0 mg rasagiline mesylate1件: Rasagiline3件: D02562 ,
D08469 ,
D10829 		1件: MAOB 💬14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
1831.0 mg RPC103----1件: 97
1841.0 mg RPC1063----1件: 97
1851.0 MIU IL-2 per day1件: Human interleukin-2---1件: 2
1861.0mg RPC1063----1件: 13
1871.2 mg Lu AE04621----1件: 6
1881.2 mg ZGN-440 for injectable suspension----1件: 193
1891.8 mg ZGN-440 for injectable suspension----1件: 193
1901.Remicade1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97
19110 mg----1件: 96
19210 mg Natura-alpha capsule----1件: 97
19310 mg/kg CNTO 136----1件: 49
19410 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
19510% intravenous immunoglobulin (IVIg)1件: Human immunoglobulin G---1件: 14
19610% liquid formulation of human immunoglobulin----1件: 14
19710% Metronidazole Ointment1件: Metronidazole3件: D00409 ,
D05016 ,
D05017 		--1件: 96
19810% nifedipine cream1件: Nifedipine1件: D00437 4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 50
19910% Nitroglycerine in Propylene Glycol, USP2件: Nitroglycerin,
Propylene glycol		2件: D00078 ,
D00515 		--1件: 51
20010-mg dose of E5501 2G tablet----1件: 63
20110-mg dose of E5501 cyclodextrin oral solution----1件: 63
20210-mg dose of E5501 lipid-based oral----1件: 63
20310-mg dose of E5501-P21% powder----1件: 63
20410-nitro-9(E)-octadec-9-enoic acid----1件: 86
205100----2件: 6, 97
206100 mg----1件: 97
207100 mg AP1189----1件: 222
208100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC----1件: 299
209100 mg ELX /50 mg TEZ /75 mg IVA FDC----1件: 299
210100 mg ELX/50 mg TEZ /75 mg IVA FDC----1件: 299
211100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination----1件: 299
212100 mg LX3305 QD----1件: 46
213100 mg TEZ/150 mg IVA FDC----1件: 299
214100 mg VX-445 /50 mg TEZ/75 mg IVA FDC----1件: 299
215100 mg VX-445/50 mg TEZ /75 mg IVA FDC----1件: 299
216100 mg/m2 dose----1件: 299
217100 µg Brimonidine Tartrate Implant1件: Brimonidine2件: D02076 ,
D07540 		3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 90
218100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC----1件: 299
219100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC----1件: 299
220100-mg ELX / 50-mg TEZ / 75 -mg----1件: 299
221100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC----1件: 299
222100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC----1件: 299
223100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC----1件: 299
224100-mg VX-445 /50-mg TEZ/75-mg----1件: 299
225100-mg VX-445/50-mg TEZ/75-mg IVA FDC----1件: 299
2261000 IU D3----1件: 96
22710000IU vitamin D1件: Vitamin D---1件: 13
2281000mg RTX Group----1件: 46
229100g ELX / 50mg TEZ / 75mg IVA----1件: 299
230100mcg rhPTH(1-84)1件: Parathyroid hormone1件: D05364 2件: PTH1R,
PTH2R 💬		3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235
231100mg ELX/50mg TEZ /75mg IVA----1件: 299
232100mg VX-445/50mg TEZ /75mg IVA FDC----1件: 299
233111JC101----1件: 25
234118-42-3----1件: 46
23511C-ACETATE2件: Acetate,
Acetic acid C-11		---3件: 13, 86, 88
23611C-BMS-986196----1件: 13
23711C-CSar----2件: 93, 94
23811C-flumazenil1件: Flumazenil1件: D00697 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 206
23911C-MCI----1件: 13
24011C-PBR28----2件: 6, 13
24111C-PiB----2件: 6, 13
24211C-Raclopride1件: Raclopride---1件: 6
24311C]-methionine1件: Methionine2件: D00019 ,
D04983 		--1件: 34
24411C]-PK-11195----1件: 13
24511C]flumazenil1件: Flumazenil1件: D00697 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 13
24611C]PBR28----1件: 6
24711C]SMW139----1件: 6
24812 lead electrocardiogram----1件: 19
24912 mg/kg GSK2402968----1件: 113
25012-Lead ECG----2件: 140, 144
251120 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
252124I-AT03----1件: 28
253124I-labeled monoclonal antibody Mu 11-1F4----1件: 28
254124I-p5+14 Injection----1件: 28
255125----1件: 6
256129Xe Hyperpolarized----1件: 86
257129Xe Small and Large Human Lung Coil----1件: 299
25812S-IT----1件: 19
25913 valent conjugated pneumococcal vaccine----1件: 265
26013-15mg/kg/d Ursodeoxycholic----1件: 93
26113-PCV Booster----1件: 13
26213-valent pneumococcal conjugate vaccine----2件: 46, 53
26313-valent pneumococcal conjugate vaccine (13-PCV)----1件: 13
26413-valent pneumococcal conjugated vaccine (PCV13)----1件: 96
2651393641-34-3----1件: 13
26613^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)1件: Spirulina platensis---1件: 299
26713NH3 PET/CT scan----1件: 84
268146368----1件: 271
26914C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration----3件: 13, 96, 97
27015 mg fampridine-SR (4-aminopyridine, 4-AP)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
27115 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD1件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
27215 mg QD PF-066497511件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
27315 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
27415 O Water1件: Water1件: D00001 --1件: 19
27515 or 45 mg----1件: 67
27615-O labeled water1件: Water1件: D00001 --1件: 46
277150 mg----1件: 97
278150 mg double-blinded secukinumab1件: Secukinumab1件: D09967 1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
279150 mg GSK1265744B----1件: 265
280150 mg LX3305 QD----1件: 46
281150 mg open-label secukinumab1件: Secukinumab1件: D09967 1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
282150-mg IVACAFTOR1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
2831500mg mesalazine pellets1件: Mesalazine1件: D00377 --1件: 97
284150mg CXA-101件: CXA-10---1件: 86
285150mg IVACAFTOR1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
28615N ammonium chloride (15NH4Cl)2件: Ammonium chloride,
Chloride ion		1件: D01139 --1件: 251
28715N2-tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 97
28815O H2O----1件: 6
28915O]H2O----1件: 6
29016,5% Cutaquig----1件: 65
2911639325-43-1----1件: 254
2921643368-58-4----2件: 53, 160
29317,21-Dihydroxypregna-1,4-diene-3,11,20-trione----1件: 41
294171----1件: 86
29517beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one----1件: 75
29617ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one----1件: 75
29718 FDG----1件: 145
29818-22mg/kg/d Ursodeoxycholic----1件: 93
29918-F]DPA-714----1件: 127
30018-FDTBZ----1件: 6
30118F florbetaben1件: Florbetaben (18F)---1件: 6
30218F- DTBZ----1件: 6
30318F-AV-1331件: Florbenazine F-18---1件: 6
30418F-AV-1451----3件: 5, 7, 127
30518F-AV-45----2件: 6, 127
30618F-deoxyglucose (FDG)----1件: 57
30718F-DOPA----2件: 6, 75
30818F-DOPA PET----1件: 6
30918F-DPA-714 and 18F-FDG1件: Fludeoxyglucose (18F)---1件: 13
31018F-DTBZ----1件: 6
31118F-DTBZ AV-133----1件: 6
31218F-FDG1件: Fludeoxyglucose (18F)---13件: 5, 6, 7, 8, 13, 41, 46, 53, 84, 85, 96, 127, 300
31318F-fluorodeoxyglucose----1件: 84
31418F-FSPG1件: Florilglutamic acid F-18---1件: 84
31518F-FTC-146----1件: 206
31618F-GE-1801件: Flutriciclamide F-18---1件: 46
31718F-PM-PBB3----1件: 13
31818F-RO6958948----3件: 5, 7, 127
31918F] LBT-999----1件: 6
32018F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane----1件: 6
32118F]DPA-714----2件: 13, 127
32218F]FE-PE2I----1件: 6
32318F]Fluoride----1件: 271
32418F]MC225----1件: 6
32518F]PEG-Folate1件: Folic acid1件: D00070 --2件: 41, 46
32618FDG PET/CT scan----1件: 84
32719 nor vitamin d1件: Vitamin D---1件: 13
3281[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-----1件: 6
3291[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea----1件: 6
3301[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-----1件: 6
3311[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea----1件: 6
3321H-Pyrazol1件: Pyrazole---5件: 2, 28, 46, 75, 154
3331mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
3341mg RPC1063----1件: 96
3351mg/kg/hr TXA intravenous infusion till the last suture----1件: 70
3361mL prefilled syringes----1件: 107
3372 - Excipients----1件: 13
3382 mA Transcranial Direct Current Stimulation----1件: 13
3392 mg perampanel1件: Perampanel1件: D08964 4件: GRIA1,
GRIA2,
GRIA3,
GRIA4 💬		16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬1件: 6
3402 million hMSC/kg----1件: 46
3412 ml of whole blood sample will be collected on EDTA tube1件: Edetic acid8件: D00052 ,
D00571 ,
D01802 ,
D03943 ,
D03944 ,
D03945 ,
D03946 ,
D03947 		--1件: 51
3422 x 10 mg Natura-alpha capsules----1件: 97
3432% Chlorhexidine solution wipes1件: Chlorhexidine4件: D00858 ,
D01345 ,
D03463 ,
D07668 		--1件: 299
3442% lignocaine1件: Lidocaine3件: D00358 ,
D02086 ,
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 84
3452% sodium chondroitin sulfate2件: Chondroitin sulfate,
Sulfate ion		---1件: 226
3462',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid----1件: 28
3472'-Fucosyllactose----2件: 96, 97
3482'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING1件: Ribose---1件: 131
3492'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID1件: Ribose---1件: 131
3502(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID----2件: 19, 65
3512,3-dihydroxybutanedioic acid----1件: 299
3522,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide----1件: 6
3532-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid1件: Benzoic acid1件: D00038 --1件: 51
3542-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester----1件: 13
3552-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat----1件: 28
3562-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate----1件: 28
3572-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide----1件: 86
3582-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE----2件: 6, 162
3592-amino-4-(methyl[11C]sulfanyl)butanoic acid2件: Butyric Acid,
Methionine		3件: D00019 ,
D04983 ,
D05866 		--1件: 34
3602-aminoethanethiol1件: Cysteamine2件: D03634 ,
D03635 		--2件: 19, 299
3612-CdA1件: Cladribine1件: D01370 1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 13
3622-CdA, 2-chloro-2'-deoxy-beta-D-adenosine2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3632-CdA, 2-chloro-2'-deoxy-ß-D-adenosine2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3642-CdA, 2-chloro-2?-deoxy-beta-D-adenosine2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3652-CdA, 2-chloro-2?-deoxy-ß-D-adenosine2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3662-CdA, 2-chloro-2’-deoxy-beta-D-adenosine2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3672-CdA, 2-chloro-2’-deoxy-ß-D-adenosine2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3682-chloro-2'-deoxy-beta-D-adenosine (2-CdA)2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3692-chloro-2'-deoxy-ß-D-adenosine (2-CdA)2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3702-chloro-2'-deoxyadenosine (2-CdA)1件: Cladribine1件: D01370 1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 13
3712-chloro-2'-deoxyadenosine, 2CdA----1件: 13
3722-chloro-2?-deoxy-beta-D-adenosine1件: Adenosine1件: D00045 4件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3 💬		12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3732-chloro-2?-deoxy-ß-D-adenosine1件: Adenosine1件: D00045 4件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3 💬		12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3742-chloro-2’-deoxy-beta-D-adenosine1件: Adenosine1件: D00045 4件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3 💬		12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3752-chloro-2’-deoxy-beta-D-adenosine (2-CdA)2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3762-chloro-2’-deoxy-ß-D-adenosine1件: Adenosine1件: D00045 4件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3 💬		12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3772-chloro-2’-deoxy-ß-D-adenosine (2-CdA)2件: Adenosine,
Cladribine		2件: D00045 ,
D01370 		5件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3,
RRM1 💬		17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
3782-chloro-2’-deoxyadenosine (2-CdA)1件: Cladribine1件: D01370 1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 13
3792-deoxy-2 [F-18] fluoro-2-d-glucose1件: D-glucose1件: D00009 --1件: 49
3802-HOBA1件: 2-(aminomethyl)phenol---1件: 46
3812-hour Holter Monitor1件: Methamidophos---1件: 19
3822-Hydroxybenzoic acid1件: Salicylic acid1件: D00097 --1件: 97
3832-HYDROXYPROPYL-BETA-CYCLODEXTRIN2件: Betadex,
Hydroxypropyl betadex		1件: D02401 --1件: 19
3842-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide1件: Acetamide---1件: 86
3852-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt1件: Hydroxide ion---1件: 46
3862.0 MIU IL-2 per day1件: Human interleukin-2---1件: 2
38720 mg----1件: 97
38820 mg BID of PF-02545920----1件: 8
38920 mg fampridine-SR (4-aminopyridine, 4-AP)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
39020 mg GA----1件: 13
39120 mg MitoQ----1件: 13
39220 mg sildenafil citrate by mouth1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
39320 mg/ml Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
394200 mg BIA 6-5121件: BIA---1件: 6
395200 mg LX3305 QD----1件: 46
396200 mg/m2 dose----1件: 299
397200 µg Brimonidine Tartrate Implant1件: Brimonidine2件: D02076 ,
D07540 		3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 90
398200106 or EMD 28162----1件: 13
399200mg Cannabidiol by capsules twice daily1件: Cannabidiol1件: D10915 2件: CNR1,
CNR2 💬		4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬1件: 46
4002011-2012 seasonal flu vaccine Intramuscular----2件: 3, 113
4012011-2012 seasonal flu vaccine Subcutaneous----2件: 3, 113
402201600930----1件: 2
403207-3120----1件: 6
40420mg daily citalopram1件: Citalopram2件: D00822 ,
D07704 		1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬1件: 8
40520mg/0.5ml GA----1件: 13
40620mg/0.5ml glatiramer acetate2件: Acetate,
Glatiramer		1件: D04318 20件: HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G 💬		32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬1件: 13
407225mg SHP647 (PF-00547659)----1件: 97
40823-PPV----1件: 13
40923-valent pneumococcal polysaccharide vaccine----3件: 13, 46, 53
41023-valent pneumococcal polysaccharide vaccine (23-PPV)----1件: 13
41123-valent polysaccharide pneumococcal vaccine----1件: 96
41223-valent polysaccharide pneumococcal vaccine (Pneumovax TM)----2件: 96, 97
4132387066----1件: 56
414240mg Amantadine HCl ER tablets1件: Amantadine2件: D00777 ,
D07441 		5件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬1件: 6
41525 mg BIA9 1067----1件: 6
41625 mg Ongentys1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
41725 mg Ontamalimab1件: Ontamalimab---2件: 96, 97
41825% MTD sodium nitrite inhalation solution1件: Nitrite---1件: 86
41925-Hydroxyvitamin D31件: Calcifediol1件: D00122 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 299
420250 mg CK-2017357----2件: 2, 11
421250 mg LX3305 BID----1件: 46
422250 mg LX3305 QD----1件: 46
423250mg mesalazine pellets1件: Mesalazine1件: D00377 --1件: 97
42425330----1件: 6
4252593----1件: 46
42625mcg rhPTH(1-84)1件: Parathyroid hormone1件: D05364 2件: PTH1R,
PTH2R 💬		3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235
42725OH-Vitamin D1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 13
4282622U90 Duramycin1件: Lancovutide---1件: 299
42926866138----1件: 28
43029180.00.00, 34681.00.00, 34681.01.00, 34681.02.00----1件: 113
431291844----2件: 246, 299
4322B3-201----1件: 13
4332L polyethylene glycol/ascorbic acid2件: Ascorbic acid,
Polyethylene glycol		2件: D00018 ,
D03370 		--1件: 97
4342mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
4352mg KPG-818 dose----1件: 49
4362S,4R-(-)-ketoconazole1件: Ketoconazole1件: D00351 1件: CYP17A1 💬6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬1件: 75
4372S,4R-(-)-ketoconazole, levoketoconazole2件: Ketoconazole,
Levoketoconazole		2件: D00351 ,
D10950 		1件: CYP17A1 💬6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬1件: 75
4383 mg [14C]-A4250 capsule----3件: 93, 297, 338
4393 mg Melatonin1件: Melatonin1件: D08170 2件: MTNR1A,
MTNR1B 💬		2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬1件: 13
4403 mg QD to 15 mg QD PF-066497511件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
4413 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)1件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
4423 mg tropicamide1件: Tropicamide1件: D00397 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
4433 mg/kg GSK2402968----1件: 113
4443 MPDN pulse + PDN----1件: 50
4453 MPDN pulse + PDN + CSA----1件: 50
4463 MPDN pulse + PDN + MTX----1件: 50
4473,4-DIAMINOPYRIDINE----2件: 12, 13
4483,4-Diaminopyridine Phosphate1件: Phosphate ion---1件: 3
4493- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate----1件: 6
4503-(3,4-Dihydroxyphenyl)-L-alanine2件: Alanine,
Levodopa		2件: D00012 ,
D00059 		5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
4513-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID1件: Pyrazole---1件: 28
4523-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-----1件: 93
4533-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt----2件: 51, 85
4543-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III)1件: Tromethamine1件: D00396 --2件: 96, 97
4553-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one.1件: Pyrazole---1件: 2
4563.2 mg intranasal carbetocin1件: Carbetocin1件: D07229 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 193
45730 or 60 mg----1件: 67
45830 or 90 mg----1件: 67
45930-hour ambulatory sampling of intestinal fluid----1件: 83
460300 mg double-blinded secukinumab1件: Secukinumab1件: D09967 1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
461300 mg LX3305 QD----1件: 46
462300mg Gemcabene1件: Gemcabene---1件: 265
4633108006977----1件: 94
464320mg Amantadine HCl ER tablets1件: Amantadine2件: D00777 ,
D07441 		5件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬1件: 6
465331731-18-1----4件: 46, 96, 97, 271
4663400930060797----1件: 36
4673400935113276----1件: 56
46835565011----1件: 46
46935mg----2件: 50, 107
47036-482-Hyaluronoglucosaminidase PH20 (rHuPH20)1件: Hyaluronidase3件: D04455 ,
D04456 ,
D06604 		--1件: 65
4713a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid----1件: 93
4723a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid----1件: 93
4733D electrocardiographic mapping (ECM)----1件: 58
4743H-cholesterol bound to albumin1件: Cholesterol1件: D00040 --2件: 259, 261
4753He Human Lung Coil----1件: 299
4763K3A-APC Protein----1件: 2
4773TC----2件: 265, 325
4784 cholesten-3-one, oxime----1件: 2
4794 mA Transcranial Direct Current Stimulation----1件: 13
4804 mg perampanel1件: Perampanel1件: D08964 4件: GRIA1,
GRIA2,
GRIA3,
GRIA4 💬		16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬1件: 6
4814 mg/kg CNTO 136----1件: 49
4824 million hMSC/kg----1件: 46
4834% chlorhexidine gluconate liquid skin cleanser1件: Chlorhexidine4件: D00858 ,
D01345 ,
D03463 ,
D07668 		--1件: 299
4844'-iodo-4'-deoxydoxorubicin1件: Iodine1件: D00108 --1件: 28
4854-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base1件: Methane---1件: 2
4864-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide1件: Pyrazole---1件: 46
4874-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide1件: Pyrazole---1件: 46
4884-Aminopyridine1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬2件: 3, 13
4894-Aminosalicylic acid1件: Aminosalicylic acid1件: D00162 --1件: 96
4904-Aminosalicylic acid extended release granules1件: Aminosalicylic acid1件: D00162 --1件: 96
4914-AP1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
4924-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione----1件: 5
4934-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione----1件: 113
4944-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione----1件: 113
4954-cholesten-3-one, oxime----2件: 2, 3
4964-cholesten-3-one,oxime----1件: 3
4974-Methylpyrazole1件: Fomepizole1件: D00707 3件: ADH1A,
ADH1B,
ADH1C 💬		9件: Alcoholic liver disease, Drug metabolism - cytochrome P450, Fatty acid degradation, Glycolysis / Gluconeogenesis, Metabolic pathways, Metabolism of xenobiotics by cytochrome P450, Pyruvate metabolism, Retinol metabolism, Tyrosine metabolism 💬1件: 301
4984-PBA----1件: 231
4994-phenylbutyrate1件: Phenylbutyric acid---2件: 251, 299
5004-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide----1件: 46
5014.2% NaCl/Inhalation solution----1件: 299
5024.5 mg Naltrexone1件: Naltrexone2件: D02095 ,
D05113 		3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
50340 mg----1件: 96
50440 mg GA----2件: 2, 13
50540 mg glatiramer acetate2件: Acetate,
Glatiramer		1件: D04318 20件: HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G 💬		32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬2件: 2, 13
50640 mg Glatiramer acetato1件: Glatiramer1件: D04318 20件: HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G 💬		32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬1件: 13
50740 mg MSB11022----5件: 46, 96, 97, 107, 271
50840 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL----1件: 107
509400 mg BIA 5-10581件: BIA---1件: 86
510400 mg LX3305 QD----1件: 46
511400 µg Brimonidine Tartrate Implant1件: Brimonidine2件: D02076 ,
D07540 		3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 90
512400mg Cannabidiol by capsules twice daily1件: Cannabidiol1件: D10915 2件: CNR1,
CNR2 💬		4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬1件: 46
51340mg of MitoQ----1件: 13
51442942019----4件: 46, 96, 97, 271
51544/154/85-C----1件: 50
51644/196/81-C----1件: 50
51745 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
518450 mg----1件: 97
5194AU76----1件: 86
5204cc of lidocaïne®----1件: 149
5214D-125 IVT Injection----1件: 90
5224D-310----1件: 19
5234D-710----1件: 299
5245 ASA, enemas, suppositories, corticosteroids----1件: 97
5255 mg Melatonin1件: Melatonin1件: D08170 2件: MTNR1A,
MTNR1B 💬		2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬1件: 13
5265 mg Montelukast1件: Montelukast2件: D00529 ,
D08229 		1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98
5275 mg Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 44
5285% glucose water solution2件: Dextrose, unspecified form,
Water		1件: D00001 --1件: 2
5295% lidocaine/5 mg/ml 0.02% estradiol compound cream2件: Estradiol,
Lidocaine		11件: D00105 ,
D00358 ,
D01413 ,
D01617 ,
D01953 ,
D02086 ,
D04061 ,
D04063 ,
D04064 ,
D04065 ,
D08127 		7件: ESR1,
ESR2,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		13件: Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬1件: 226
5305% sildenafil cream1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 50
5315,6,7,8-tetrahydrobiopterin1件: Sapropterin1件: D08505 --1件: 240
5325-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole----1件: 113
5335-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride1件: 2,4-thiazolidinedione---1件: 20
5345-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride1件: 2,4-thiazolidinedione---1件: 20
5355-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE1件: 2,4-thiazolidinedione---1件: 20
5365-amino salicylic acid1件: Salicylic acid1件: D00097 --1件: 97
5375-amino salicylic acid (5-ASA)2件: Mesalazine,
Salicylic acid		2件: D00097 ,
D00377 		--1件: 97
5385-amino-2-hydroxybenzoic acid1件: Salicylic acid1件: D00097 --1件: 97
5395-aminolevulinic acid1件: Aminolevulinic acid2件: D02908 ,
D07567 		--1件: 96
5405-Aminosalicyclic acid----1件: 97
5415-Aminosalicyl acid----1件: 96
5425-aminosalicylate (Pentasa, Ferring)----2件: 96, 97
5435-Aminosalicylic acid2件: Aminosalicylic acid,
Mesalazine		2件: D00162 ,
D00377 		--2件: 96, 97
5445-Aminosalicylic acid (5-ASA)2件: Aminosalicylic acid,
Mesalazine		2件: D00162 ,
D00377 		--1件: 97
5455-Aminosalicylic acid(5-ASA) and/or Prednisone3件: Aminosalicylic acid,
Mesalazine,
Prednisone		3件: D00162 ,
D00377 ,
D00473 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
5465-ASA1件: Mesalazine1件: D00377 --2件: 96, 97
5475-ASA (5-Aminosalicylate)1件: Mesalazine1件: D00377 --1件: 97
5485-ASA MMx1件: Mesalazine1件: D00377 --1件: 97
5495-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin1件: Chlorine---2件: 46, 271
5505-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium----1件: 8
5515-HTP----2件: 96, 97
5525-Hydroxytryptophan / Vitamin B61件: Pyridoxine2件: D02179 ,
D08454 		--1件: 206
5535-Methyl-1-Phenyl-2-1-(H)-Pyridone----1件: 228
5545-methyltetrahydrofolate and vitamin B121件: Cyanocobalamin4件: D00166 ,
D03615 ,
D03616 ,
D03617 		--1件: 299
5555-MTHF----1件: 337
5565-probe cocktail----1件: 254
55750 mg----1件: 97
55850 mg AP1189----1件: 46
55950 mg BIA 9 10671件: BIA---1件: 6
56050 mg ELX/25 mg TEZ/37.5 mg IVA----1件: 299
56150 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination----1件: 299
56250 mg Etanercept1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
56350 mg LX3305 QD----1件: 46
56450 mg Ongentys1件: Opicapone1件: D10825 1件: COMT 💬4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬1件: 6
565500 0500 0----1件: 19
566500 mg CK-2017357----2件: 2, 11
567500 mg LX3305 QD----1件: 46
5685000 IU D3----1件: 96
5695000 IU of cholecalciferol1件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 299
5705000IU vitamin D1件: Vitamin D---1件: 13
5715009111000001105----1件: 43
572500mg mesalazine pellets1件: Mesalazine1件: D00377 --1件: 97
573500mg RTX Group----1件: 46
5745057732----1件: 271
57550mcg rhPTH(1-84)1件: Parathyroid hormone1件: D05364 2件: PTH1R,
PTH2R 💬		3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235
57652069.00.01----1件: 13
577534-1508----1件: 85
578549-0261/F02-01----2件: 96, 97
579552-02----2件: 53, 299
58056/104/75-C----1件: 50
5815mg----2件: 50, 107
5826 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747----1件: 93
5836 Mercaptopurine1件: Mercaptopurine2件: D00161 ,
D04931 		1件: HPRT1 💬3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬2件: 96, 97
5846 mg/kg GSK2402968----1件: 113
5856 million hMSC/kg----1件: 46
5866% Hypertonic Saline (HS), 4mL----1件: 299
5876-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine----1件: 38
5886-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate----1件: 46
5896-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine----1件: 96
5906-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid----1件: 97
5916-ECDCA1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
5926-ethylchenodeoxycholic acid1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
5936-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one----1件: 2
5946-Mercaptopurine1件: Mercaptopurine2件: D00161 ,
D04931 		1件: HPRT1 💬3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬3件: 96, 97, 164
5956-Mercaptopurine (Puri-Nethol)1件: Mercaptopurine2件: D00161 ,
D04931 		1件: HPRT1 💬3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬1件: 96
5966-MP1件: Mercaptopurine2件: D00161 ,
D04931 		1件: HPRT1 💬3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬2件: 96, 97
597600mg Gemcabene1件: Gemcabene---1件: 265
5986036937.00.01----1件: 6
59964Cu]Cl2----1件: 171
60064CuCl2----1件: 171
60166215-101----1件: 86
602683699----1件: 96
60368Ga-BMV101----1件: 85
60468Ga-BNOTA-PRGD2----1件: 46
60568Ga-DOTA-TATE PET/MR and PET/CT imaging1件: Dotatate---1件: 238
60668Ga-DOTANOC----1件: 84
60768Ga-DOTATATE2件: Dotatate,
Dotatate gallium Ga-68		---3件: 75, 84, 238
60868Ga-DOTATATE PET/CT2件: Dotatate,
Dotatate gallium Ga-68		---1件: 84
60968Ga-FAPI----2件: 46, 300
61068Ga-NEB----3件: 46, 89, 280
6116?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-7471件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6126a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-7471件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6136a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6146a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6156a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA)1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6166a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6176a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA)1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6186a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6196a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6206a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA)1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6216a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6226a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA)1件: Obeticholic acid1件: D09360 1件: NR1H4 💬1件: Bile secretion 💬1件: 93
6236abeta - apomorphine-10,11-diol hydrochloride hemihydrate1件: Apomorphine2件: D02004 ,
D07460 		2件: DRD1,
DRD2 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
6246aß - apomorphine-10,11-diol hydrochloride hemihydrate1件: Apomorphine2件: D02004 ,
D07460 		2件: DRD1,
DRD2 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
6256R-BH41件: Sapropterin1件: D08505 --3件: 86, 124, 240
6267 mg QD to 15 mg QD PF-066497511件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
6277 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)1件: Tavapadon1件: D11431 2件: DRD1,
DRD5 💬		10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6
6287% Hypertonic Saline (HS)----1件: 299
6297% NaCl----1件: 299
6307% saline----1件: 299
6317-beta-Hydroxyepiandrosterone1件: 7-beta-Hydroxyepiandrosterone---1件: 6
6327-valent Pneumococcal Conjugate vaccine----1件: 46
63370930.00.00----1件: 46
63475----1件: 6
63575 mg Ontamalimab1件: Ontamalimab---2件: 96, 97
63675-mg IVACAFTOR1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
637750 mg metformin and 7.5 g L-citrulline daily p.o.2件: Citrulline,
Metformin		3件: D00944 ,
D04966 ,
D07706 		2件: PRKAA1,
PRKAA2 💬		20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 113
638750mg mesalazine pellets1件: Mesalazine1件: D00377 --1件: 97
639755nm Alexandrite Laser----1件: 34
64075mg CXA-101件: CXA-10---1件: 86
64175mg SHP647 (PF-00547659)----1件: 97
6428-OHdG1件: 8-hydroxy-2'-deoxyguanosine---1件: 6
64380 mg DR-6MP----1件: 96
644800 mg ibuprofen/26.6 mg famotidine2件: Famotidine,
Ibuprofen		5件: D00126 ,
D00318 ,
D01122 ,
D04490 ,
D06606 		3件: HRH2,
PTGS1,
PTGS2 💬		26件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 107
64580mg ELX / 40mg TEZ / 60mg IVA----1件: 299
64681mg aspirin1件: Acetylsalicylic acid1件: D00109 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 49
6478594739041288----1件: 46
6488699505952864----1件: 56
64989 Zirconium Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) (radiolabeled)----1件: 19
65089ZR-BEVACIZUMAB2件: Bevacizumab,
Bevacizumab zirconium Zr-89		1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 34
65189Zr-DFO-CZP----1件: 46
65289Zr-SBC-103----1件: 19
6539 mg/kg GSK2402968----1件: 113
6549% Sodium Chloride (NaCl) IV2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 78
6559-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline----1件: 46
6569-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER1件: Linoleic acid---2件: 2, 5
6579.6 mg intranasal carbetocin1件: Carbetocin1件: D07229 1件: OXTR 💬4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬1件: 193
65890 mg hydrocortisone acetate suppository with Sephure suppository applicator3件: Acetate,
Hydrocortisone,
Hydrocortisone acetate		2件: D00088 ,
D00165 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
65990 mg idrocortisone acetato in supposta con appli----1件: 97
66090 mg idrocortisone acetato in supposta con applicatore per supposte Sephure----1件: 97
66190 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
6629060X----2件: 13, 149
66395% Pure ECGC capsules 200mg----1件: 13
6649512----1件: 46
6659715X----1件: 90
6669741X----1件: 90
6679742X----1件: 90
66898% dehydrated alcohol1件: Ethanol4件: D00068 ,
D02798 ,
D04855 ,
D06542 		--1件: 298
66998-92-0----1件: 107
670980nm laser----1件: 34
67199m technetium infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 84
67299mTc-3PRGD2----1件: 46
67399mTc-Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 84
67499mTc-rhAnnexin V-128----2件: 46, 271
67599mTc-S-HYNIC Certolizumab pegol1件: Certolizumab pegol1件: D03441 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 46, 96
676: 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N-----1件: 86
677: immunoglobulina umana normale 10% per somministrazione endovenosa----1件: 14
678?-3 polyunsaturated fatty acid----1件: 96
679[11C]-GSK2256098 500 MBq1件: GSK2256098---1件: 86
680[11C]-PIB----1件: 6
681[11C]CPPC Injection----1件: 2
682[11C]MPC6827----1件: 2
683[11C]PXT012253----1件: 6
684[123I] 5-IA----1件: 6
685[123I] IBVM and SPECT imaging----1件: 6
686[123I] mZINT injection and serial dynamic SPECT imaging----1件: 6
687[123I]-IBVM----1件: 6
688[123I]-IBZM imaging----1件: 6
689[123I]B-CIT----1件: 6
690[123I]B-CIT SPECT imaging----1件: 6
691[123I]beta CIT----1件: 6
692[123I]beta CIT and SPECT imaging----1件: 6
693[123I]beta-CIT----1件: 6
694[123I]beta-CIT and SPECT imaging----1件: 6
695[123I]CLINDE----2件: 6, 13
696[123I]MNI-420----2件: 6, 8
697[123I]ß CIT----1件: 6
698[123I]ß CIT and SPECT imaging----1件: 6
699[123I]ß-CIT----1件: 6
700[123I]ß-CIT and SPECT imaging----1件: 6
701[124I]IB PF 06687234----2件: 96, 97
702[14C] AT1001----1件: 19
703[14C]-BIA 9-10671件: BIA---1件: 6
704[18F] APN-1607----1件: 5
705[18F] CFPyPB----1件: 6
706[18F] FES----1件: 86
707[18F] GE-180----1件: 2
708[18F] LBT-999 PET----1件: 6
709[18F] PBR06----2件: 6, 13
710[18F] PI-2620----1件: 6
711[18F]-FBA-A20FMDV2----1件: 85
712[18F]-FEPPA----2件: 6, 13
713[18F]-FLT-PET/CT scans----1件: 34
714[18F]-PI2620----1件: 5
715[18F]DPA-714 PET----1件: 2
716[18F]DPA-714 PET scan----1件: 6
717[18F]FDOPA----2件: 6, 17
718[18F]FDOPA PET/CT----1件: 6
719[18F]Florbetaben----1件: 28
720[18F]Florbetapir----1件: 5
721[18F]Florbetapir PET imaging----1件: 13
722[18F]flumazenil1件: Flumazenil1件: D00697 16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 206
723[18F]Fluoro-2-deoxy-2-D-glucose1件: D-glucose1件: D00009 --2件: 86, 88
724[18F]FP-R01-MG-F2----2件: 85, 94
725[18F]FPEB----3件: 6, 8, 206
726[18F]FPEB PET imaging----1件: 206
727[18F]FSPG----2件: 96, 97
728[18F]MK-9470----1件: 6
729[18F]MNI-1126----1件: 6
730[18F]MNI-444----1件: 6
731[18F]MNI-815 (MNI-815)----1件: 5
732[18F]MNI-952----1件: 5
733[18F]MNI-958----1件: 5
734[18F]MPPF----1件: 6
735[18F]NOS----1件: 6
736[18F]P17-059----1件: 6
737[18F]PBR06----1件: 2
738[18F]PI-2620----2件: 6, 127
739[18F]T807 ([18F]MNI-777)----2件: 5, 6
740[18F]UCB-2897----1件: 6
741[21CFR640.30] Plasma from 18 - 25 year old volunteer donors----1件: 6
742[64]Cu Macrin----1件: 84
743[68Ga]CBP8----1件: 85
744[C-11]Methylreboxetine----1件: 13
745[C-11]PBR28----1件: 13
746[C11]PK-1195 PET scan----1件: 13
747[F-18] Fluorodopa Positron Emission Tomography----1件: 6
748[F-18]PBR06----2件: 13, 17
749[F-18]SDM-8----1件: 13
750[F18]-FDDNP----1件: 5
751[Zr-89]Oxine-labeled leukocytes PET/MR1件: Oxyquinoline1件: D05321 --1件: 13
752 LNP023 HYDROCHLORIDE SALT----5件: 61, 62, 66, 109, 222
753ÁCIDO GADOBÉNICO----1件: 96
754Ácido risedrónico----1件: 274